Our recent activity

Asabys launches a new €200m fund to invest in biotech & healthtech

The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the Alantra Investment Pool (Alantra & Mutua).

SAHII 2 will invest in digital health, medtech and biotech companies, developing disruptive solutions with solid scientific evidence to improve patient outcomes.

With this new vehicle Asabys consolidates itself as the leading venture capital firm in health technologies in Southern Europe. The firm was founded by Josep Ll. Sanfeliu and Clara Campàs in 2018 with the support of Banc Sabadell as anchor investor and Alantra as strategic partner.

Asabys has announced today the launch of a new fund, Sabadell Asabys Health Innovation Investments II (SAHII 2), to continue investing in health innovation technologies and consolidate its presence as leading venture capital firm in the space in Southern Europe.

Headquartered in Barcelona, Asabys was founded by Josep Ll. Sanfeliu and Clara Campàs in 2018 with the support of Alantra as strategic partner. Banc Sabadell, who was the anchor investor of the firm’s first fund, will also be the main investor in this new vehicle. With a target size of €200 million, SAHII 2 aims to invest in European projects with disruptive technologies and solid scientific evidence, from early phases to commercialization stages.

With close to 120 million euros in AUM, Asabys has invested in 13 companies (1 exited) in the biopharma, medtech and digital health sectors. The experience acquired in these verticals positions Asabys as a unique firm diversifying its portfolio across biopharma and healthtech companies, generating synergies and acquiring unique know-how.

Josep Ll. Sanfeliu comments “Asabys was born with the mission to invest health innovation across the board and the reality is that the space has been converging technologically, creating countless opportunities to solve the challenges that medicine has nowadays by integrating biology or pharmacy with nanotechnologies, digitalization or artificial intelligence.”

Clara Campàs adds “With this second fund we will continue investing in the creation of new companies, as well as consolidate existing ones, with the goal to transform disruptive science in real solutions for patients.”

Raúl Rodríguez, Deputy Director General of Banc Sabadell and Director of BSCapital, mentions: “The investment of Banc Sabadell in SAHII 2 reflects the bank’s sustained commitment for innovation and emerging industries that provide impactful solutions to society, hand in hand with managers and teams that work with rigor and professionalism.”

“We are very happy to support our partners Josep Lluis, Clara and the rest of the Asabys team in the launch of this new fund, which offers a new opportunity to provide access to our investors to highly-specialized alternative asset management products in VC-related strategies”, said Jacobo Llanza, CEO of Alantra Asset Management.

About Asabys Partners

Asabys Partners is a venture capital firm specialized in the healthcare sector, founded by Josep Ll. Sanfeliu and Clara Campàs and participated by Alantra. With close to €120 Million in AUM and 13 portfolio companies (1 exited), Asabys invests in highly innovative and disruptive companies covering unmet medical needs in the biopharma and healthtech verticals. Its first investment vehicle, Sabadell Asabys Health Innovation Investments SCR, SA, was launched in 2019 and is backed by Banc Sabadell as anchor investor. https://asabys.com/

Internal
September 15, 2022

Asabys launches a new €200m fund to invest in biotech & healthtech

READ THIS NEWS IN SPANISH The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the…
Portfolio
September 13, 2022

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage…
Portfolio
July 13, 2022

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M

READ THIS NEWS IN SPANISH ● Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors ● Funding will support next…